Abstract: The present invention belongs to the field of nuclear medicine and relates to a Granzyme B-targeting complex, a radiopharmaceutical, a preparation method therefor and a use thereof. A structure of the Granzyme B-targeting complex is shown in formula (I), where R is any one of a bifunctional chelating group or a derivative thereof for radionuclide labeling. The Granzyme B-targeting complex provided by the present invention can be prepared into the Granzyme B-targeting radiopharmaceutical through radionuclide labeling. The Granzyme B-targeting radiopharmaceutical provided is simple to prepare and has better pharmacokinetic characteristics and in vivo metabolic stability than other Granzyme B-targeting drugs. The expression level of Granzyme B in vivo can be monitored noninvasively by nuclear medicine imaging.

Abstract: The present invention relates to the field of biomedicine, and discloses a pyrazolopyrimidine compound, a pharmaceutical composition, and an application therefor, the oxygen-containing substituted pyrazolopyrimidine compound having the structure shown in formula (I). The oxygen-containing substituted pyrazolopyrimidine compound having the structure shown in formula (I) provided in the present invention or a pharmaceutically acceptable salt, a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, or a prodrug thereof demonstrate excellent inhibitory activity against TRK kinase, and demonstrate good anti-tumour activity at the animal level.